Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16906034 | 0.77 | PKM (0.34) | — | |
| SCHEMBL16111049 | 0.76 | RET (0.33) | — | |
| SCHEMBL3165276 | 0.74 | — | — | |
| SCHEMBL28788473 | 0.71 | — | — | |
| SCHEMBL23082916 | 0.71 | — | — | |
| SCHEMBL19498011 | 0.71 | DRD2 (0.32) | — | |
| SCHEMBL18949093 | 0.70 | KDM5B (0.32) | — | |
| SCHEMBL3154656 | 0.69 | BRD4 (0.35) | — | |
| SCHEMBL23062876 | 0.68 | BRD4 (0.40) | — | |
| SCHEMBL23062882 | 0.68 | BRD4 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416263-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2023-12-28 | — | — | US | disclosed |
| US-11834455-B2 | Carm1 inhibitors and uses thereof | Epizyme, Inc. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834455-B2 | Carm1 inhibitors and uses thereof | Epizyme, Inc. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834455-B2 | Carm1 inhibitors and uses thereof | Epizyme, Inc. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230279020-A9 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230279020-A9 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230279020-A9 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20210155631-A1 | CARM1 INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2021-05-27 | — | — | US | disclosed |
| US-10633389-B2 | CARM1 inhibitors and uses thereof | Epizyme, Inc. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20190135819-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2019-05-09 | — | — | US | disclosed |
| US-8680290-B2 | Isoxazoline derivatives and their use as herbicides | SYNGENTA LIMITED (GB) | 2014-03-25 | — | — | US | disclosed |
| US-8680290-B2 | Isoxazoline derivatives and their use as herbicides | SYNGENTA LIMITED (GB) | 2014-03-25 | — | — | US | disclosed |
| CN-101052628-B | Isoxazoline derivatives and herbicidal use thereof | SYNGENTA LTD | 2011-07-27 | — | — | CN | disclosed |
| EP-1789401-B1 | ISOXAZOLINE DERIVATIVES AND THEIR USE AS HERBICIDES | SYNGENTA LTD (GB) | 2010-03-03 | — | — | EP | disclosed |
| EP-1789401-B1 | ISOXAZOLINE DERIVATIVES AND THEIR USE AS HERBICIDES | SYNGENTA LTD (GB) | 2010-03-03 | — | — | EP | disclosed |
| US-20080139390-A1 | Isoxazoline Derivatives and Their Use as Herbicides | SYNGENTA LIMITED (GB) | 2008-06-12 | — | — | US | disclosed |
| US-20080139390-A1 | Isoxazoline Derivatives and Their Use as Herbicides | SYNGENTA LIMITED (GB) | 2008-06-12 | — | — | US | disclosed |
| US-20080139390-A1 | Isoxazoline Derivatives and Their Use as Herbicides | SYNGENTA LIMITED (GB) | 2008-06-12 | — | — | US | disclosed |
| EP-1789401-A1 | ISOXAZOLINE DERIVATIVES AND THEIR USE AS HERBICIDES | Syngenta Limited (GB) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006024820-A1 | ISOXAZOLINE DERIVATIVES AND THEIR USE AS HERBICIDES | SYNGENTA LIMITED (GB) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210155631-A1 | CARM1 INHIBITORS AND USES THEREOF | CARM1, TIAM1, ADRM1 | EPHX2 2074/4885 |
| US-20080139390-A1 | Isoxazoline Derivatives and Their Use as Herbicides | MTX1, MTX2, CHRM1 | EPHX2 373/4885 |
| US-20230279020-A9 | CARM1 INHIBITORS AND USES THEREOF | CARM1, TIAM1, ADRM1 | EPHX2 2074/4885 |
| US-11834455-B2 | Carm1 inhibitors and uses thereof | CARM1, TIAM1, ADRM1 | EPHX2 2094/4885 |
| US-10633389-B2 | CARM1 inhibitors and uses thereof | CARM1, TIAM1, ADRM1 | EPHX2 2074/4885 |
| US-20190135819-A1 | CARM1 INHIBITORS AND USES THEREOF | CARM1, TIAM1, ADRM1 | EPHX2 2074/4885 |
| US-20230416263-A1 | CARM1 INHIBITORS AND USES THEREOF | CARM1, TIAM1, ADRM1 | EPHX2 2074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.